For a clinician managing a patient with type 2 diabetes, hypertension, and chronic kidney disease, the treatment pathway is a tangle of competing guidelines, drug interactions, and individual risk factors. The standard of care is a manual, time-intensive synthesis of disparate data points. A London-based startup, Metadvice, is betting that a carefully tuned AI engine can help untangle that knot, starting with the complex world of cardiometabolic disease [metadvice.com, retrieved 2026].
The company, founded in 2019, is developing a software-as-a-service platform designed to integrate patient records, clinical guidelines, and real-world outcomes to support treatment decisions [LinkedIn, retrieved 2026]. Its most concrete validation to date is not venture capital, but a £229,830 grant from UK Research and Innovation (UKRI) to develop its AI engine specifically for high-lipid management, part of a larger £328,328 project [UKRI Gateway to Research, project record]. In the world of regulated clinical AI, where peer-reviewed evidence and regulatory navigation are as critical as code, this kind of non-dilutive, targeted funding is a meaningful signal of technical plausibility.
A Clinical Wedge in Chronic Disease
Metadvice’s initial focus is deliberately narrow, targeting a cluster of interconnected, lifelong conditions. The platform is designed to assist with type 2 diabetes, hypertension, hypercholesterolemia, chronic kidney disease, heart failure, atrial fibrillation, and polycystic ovary syndrome [metadvice.com, retrieved 2026]. By concentrating on this cardiometabolic nexus, the company aims to build a deep, clinically valid model of disease progression and treatment response. The software is intended to prioritize high-risk patients, suggest appropriate clinicians for referral, and personalize treatment pathways, functioning either as a standalone application or integrated into a hospital's electronic medical record system [metadvice.com, retrieved 2026].
The Unconventional Founding Trio
The team behind Metadvice reads less like a typical healthtech startup and more like a cross-disciplinary task force assembled for a complex problem. This blend of backgrounds is its most distinctive asset.
| Role | Name | Key Background |
|---|---|---|
| Co-Founder & CTO | André Jaun | Former nuclear fusion researcher at EPFL; associate professor of scientific computing [HIN, April 2025]. |
| Co-Founder & Chair | Richard W. Barker, OBE | Visiting Professor at King’s College London; founding director of the UK Health Innovation Network [The Hastings Center, retrieved 2026]. |
| Co-Founder & Director | Serge Umansky, PhD | Over 20 years in investment management and private equity following a background in mathematical modeling [metadvice.com, retrieved 2026]. |
| Managing Director | Dr Jonathan Serjeant | A practicing GP in Sussex, leading clinical strategy and commercial development [LinkedIn, Dr Jonathan Serjeant, retrieved 2026]. |
This combination brings together high-performance computing expertise, deep National Health Service policy connections, financial acumen, and, crucially, day-to-day clinical practice. The presence of a practicing GP like Dr. Serjeant in a leadership role is a deliberate anchor to real-world clinical workflows and credibility.
Traction Beyond the Checkbook
Without a disclosed venture round, Metadvice’s progress is measured in grants, partnerships, and procurement readiness. The UKRI grant is the most tangible. The company has also collaborated with Innosuisse and Bern’s University Hospital (Inselspital) on AI-enabled care objectives, indicating academic-clinical validation work is underway [HIN, March 2026]. In 2024, it published a service-definition document for the UK’s G-Cloud 14 framework, a critical step for any software vendor hoping to sell to UK government bodies, including the NHS [applytosupply.digitalmarketplace.service.gov.uk, April 2024]. Furthermore, it won first place in the Health Innovation Network (HIN) & Swiss Health Startups (SHS) Innovation Challenge in June 2024, selected by a jury of industry experts [HIN, June 2024].
The Regulatory and Competitive Landscape
For any clinical decision support tool, the path to adoption is paved with regulatory scrutiny and established competitors. Metadvice’s platform would likely be classified as a Software as a Medical Device (SaMD) in many jurisdictions, requiring a rigorous demonstration of safety and efficacy to regulators like the UK’s MHRA or the U.S. FDA before it can be actively recommended for treatment. The company’s grant work and hospital collaborations appear to be early steps in building that evidence base.
The competitive set includes large, entrenched players like Wolters Kluwer’s UpToDate Expert AI, which also leverages AI to synthesize medical evidence. Metadvice’s potential differentiation rests on a few key hypotheses:
- Depth over breadth. A hyper-focused model on cardiometabolic diseases could outperform more generalized tools.
- Real-world data integration. The ability to incorporate local outcome data, not just published guidelines, for personalized pathways.
- Dual revenue model. Serving both health systems and pharmaceutical companies seeking real-world evidence for drug development [metadvice-ai.com, retrieved 2026].
The company’s answer to these challenges appears to be a slow-and-steady approach, prioritizing grant-funded validation and clinical partnerships over rapid commercial scaling. This is a patient strategy for a patient-facing problem.
The Road to the Clinic
The next twelve months for Metadvice will be defined by the execution of its UKRI grant project and the pursuit of its first paid commercial deployments, likely within the UK or Swiss healthcare systems where it has established connections. A logical next step would be a seed round to scale its engineering team and initiate the formal regulatory submission process, building on the data generated from its grant work. The company’s participation in a Swiss National Medtech Team roadshow to Boston in late 2024 also hints at longer-term ambitions for the U.S. market [Venturelab, October 2024].
For the millions of patients living with complex, co-occurring conditions like diabetes and heart failure, the standard of care today is often a fragmented experience. Management relies on a primary care physician or specialist manually coordinating across siloed guidelines, a process vulnerable to oversight and inefficiency. Metadvice’s bet is that an AI trained on a deep well of clinical data can become a consistent, informed second opinion, helping to ensure the right patient gets the right intervention at the right time. It’s a humane engineering challenge, and one this unusual team is attempting to solve one grant, and one algorithm, at a time.
Sources
- [UKRI Gateway to Research, project record] UKRI Gateway to Research, project record | https://gtr.ukri.org/projects?ref=52685
- [metadvice.com, retrieved 2026] Metadvice - Clinical Decision Intelligence | https://www.metadvice.com/
- [LinkedIn, retrieved 2026] Metadvice | LinkedIn | https://www.linkedin.com/company/metadvice
- [HIN, April 2025] Massgeschneiderte Medizin dank KI: Die Lösung von Metadvice. | https://www.hin.ch/de/blog/2024/massgeschneiderte-medizin-dank.cfm
- [The Hastings Center, retrieved 2026] Richard W. Barker profile | https://www.thehastingscenter.org/person/richard-w-barker/
- [LinkedIn, Dr Jonathan Serjeant, retrieved 2026] Dr Jonathan Serjeant profile | https://www.linkedin.com/in/dr-jonathan-serjeant-0a1b0b1b/
- [HIN, March 2026] Médecine sur mesure grâce à l’IA: la solution de Metadvice. | https://www.hin.ch/fr/blog/2024/medecine-sur-mesure-grace-ia-l.cfm
- [applytosupply.digitalmarketplace.service.gov.uk, April 2024] G-Cloud 14 Service Definition Document | https://assets.applytosupply.digitalmarketplace.service.gov.uk/g-cloud-14/documents/719829/389858029905361-service-definition-document-2024-04-30-1100.pdf
- [HIN, June 2024] HIN & SHS Innovation Challenge winner announcement | https://www.hin.ch/de/blog/2024/massgeschneiderte-medizin-dank.cfm
- [metadvice-ai.com, retrieved 2026] Metadvice collaborate page | https://metadvice-ai.com/company/collaborate/
- [Venturelab, October 2024] Metadvice: The Venture Leader Medtech accelerating personalised and complex disease care | https://www.venturelab.swiss/Metadvice-The-Venture-Leader-Medtech-accelerating-personalised-and-complex-disease-care